Search

Stefan A Ambs

from Silver Spring, MD
Age ~63
Get Report
Also known as:
Stefa Ambs, Atefan Ambs
Phone and address:
10603 Lorain Ave, Silver Spring, MD 20901
(301) 681-6189
Related to:
Scarlett S Horton, 64Florie B Mcfarlane, 87Nancy Martinez, 56Victor A Martinez, 38Sheila Martinez, 38Sheila Harrington, 67Dolores A Swenson, 61
Connected to:
Albert G Ambs, 82Andrew L Ambs, 54Mike T Ambs, 50Ryan M Ambs, 48Tanner W Ambs, 34Anna L Ambuehl, 44Barbara A Ambuehl, 63Lori R Ambuehl, 67Melvin Ambuehl, 79Shelly E Ambuehl, 58

Stefan Ambs Phones & Addresses

  • 10603 Lorain Ave, Silver Spring, MD 20901 (301) 681-6189
  • 17 Ford St, Dedham, MA 02026 (781) 329-6919 (781) 407-0193
  • 455 Albemarle Rd, Newtonville, MA 02460
  • Newton, MA
  • Bethesda, MD
  • 2713 Norfolk St, San Mateo, CA 94403
  • 17 Ford St, Dedham, MA 02026 (781) 329-6919

Publications

Us Patents

P53 And Vegf Regulate Tumor Growth Of Nos2 Expressing Cancer Cells

View page
US Patent:
20070056049, Mar 8, 2007
Filed:
Aug 1, 2005
Appl. No.:
11/195006
Inventors:
Stefan Ambs - Newtonville MA, US
Curtis Harris - Garrett Park MD, US
Assignee:
The Govt. of the USA as represented by the Secretary of the Dept. of Health & Human Services - Rockville MD
International Classification:
A61K 49/00
G01N 33/53
A61K 31/198
A61K 31/195
US Classification:
800003000, 435007920, 514565000
Abstract:
The invention provides, for example, in vitro and in vivo methods for screening modulators of NOS-2 activity using p53 mutant cells, methods of predicting the benefit of administering NOS-2 inhibitors to a cancer patient, and methods of treating cancer by administering NOS-2 inhibitors to patients with p53 mutant cancers.

Manganese Superoxide Dismutase Val16Ala Polymorphism Predicts Resistance To Chemotherapeutic Drug Cancer Therapy

View page
US Patent:
20090136952, May 28, 2009
Filed:
Nov 11, 2008
Appl. No.:
12/268655
Inventors:
Stefan Ambs - Silver Spring MD, US
Brenda Boersma - Hagerstown MD, US
Assignee:
Human Services - Rockville MD
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
The present invention provides, for the first time, the finding that the manganese superoxide dismutase Val16Ala polymorphism is significantly associated with prognosis for cancer patients treated with chemotherapeutic drug therapy. The alanine allele is a novel biomarker that predicts poor response and poor outcome to chemotherapeutic drug cancer therapy. Conversely, the valine allele predicts a good response and a good outcome to chemotherapeutic drug cancer therapy. Therefore, a genotype assay can be used to determine which alleles a subject is carrying, and subsequently this information can be used to determine if chemotherapeutic drug therapy is appropriate, and to customize therapy according to the patient's MnSOD genotype.

Microrna-Based Methods And Compositions For The Diagnosis, Prognosis And Treatment Of Prostate Related Disorders

View page
US Patent:
20110054009, Mar 3, 2011
Filed:
Feb 27, 2009
Appl. No.:
12/919888
Inventors:
Carlo M. Croce - Columbus OH, US
Stefan Ambs - Silver Spring MD, US
Assignee:
THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION - Columbus OH
International Classification:
A61K 31/7088
C12Q 1/68
C12Q 1/44
C07H 21/02
C12N 5/09
C12N 9/99
A61P 35/00
G01N 33/49
US Classification:
514 44 A, 435 6, 435 19, 536 245, 435375, 435183, 73 5301
Abstract:
Methods and compositions for the diagnosis, prognosis and/or treatment of prostate associated disorders are disclosed.
Control profile
Stefan A Ambs from Silver Spring, MD, age ~63 Get Report